Merck is trading at $143.66, down 3.17%, with DZ Bank’s downgrade a potential negative sentiment catalyst. - DZ Bank downgraded Merck to Hold from Buy and set a $153 price target on November 3. - Merck announced the start of a Phase 3 Ohtuvayre trial, but coverage reported shares falling despite the news; the announcement does not clearly explain the decline. - The broader market was mixed, offering no clear market-wide explanation.